Share this article
Health Canada Approval Enables Quick and Accurate Blood Testing
TORONTO, April 27, 2021 /CNW/ - AA Pharma, a Canadian company focused on legacy pharmaceutical products, has secured the exclusive Canadian rights for the use of a blood analyzer for patients prescribed Clozapine. This medication, indicated for patients with Treatment Resistant Schizophrenia, requires regular blood monitoring.
Sight Diagnostics
Ⓡ received Health Canada approval for its Sight OLO
Ⓡ analyzer, which performs Complete Blood Count (CBC) tests, the most commonly ordered blood test because it offers insight into the status of a patient s overall health. The analyzer leverages a patented method of digitizing blood samples and is built with high-powered microscopes, computer vision, and artificial intelligence, providing accurate results in minutes with only two drops of blood. It is also the first CBC analyzer that is FDA 510(k) cleared for blood taken directly from either a
New rapid testing at Windsor Regional Hospital will allow them to assess much more quickly whether in-patients in hospital are carrying the COVID-19 virus.
Implementation of the GeneXpert instrument by laboratory staff and the vendor, Inter Medico, is complete and Medical Laboratory Technologists have been trained in the use of the instrument, which was also validated by testing known samples to verify performance and accuracy.
The hospital says they can now test up to 200 individuals per week, which is the maximum amount of weekly tests available for use due to an international supply shortage.
Article Continues Below Local Sponsor Message